Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL1279619 | 1.00 | GSR (0.50) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL28473423 | 0.98 | OTC (0.49) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL31571149 | 0.95 | OTC (0.47) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL6803653 | 0.95 | GSR (0.58) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL4749671 | 0.95 | GSR (0.58) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL578156 | 0.95 | GSR (0.58) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL573880 | 0.95 | GSR (0.58) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL578155 | 0.95 | GSR (0.58) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL7650333 | 0.95 | OTC (0.49) | GSRCYP1A2OTCGRM8GRM6 | |
| Arginine SCHEMBL2404175 | 0.95 | OTC (0.49) | GSRCYP1A2OTCGRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260009043-A1 | METHOD FOR PRODUCING SPERMIDINE | ZHUO HONG CHAOYUAN BIOTECHNOLOGY WUXI CO LTD (CN) | 2026-01-08 | — | — | US | claimed |
| EP-4565608-A2 | PHARMACEUTICAL COMPOSITIONS OF FUSION PROTEINS AND METHODS OF USE THEREOF | Alexion Pharmaceuticals, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4539881-A1 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | Bioverativ USA Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119736219-A | Escherichia coli engineering bacteria for producing spermidine and application | 西安卓虹超源生物科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119709567-A | Modification of Serratia marcescens and application of Serratia marcescens in spermidine production | 西安卓虹超源生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2025061082-A1 | METHOD FOR PRODUCING SPERMIDINE | 西安卓虹超源生物科技有限公司 | 2025-03-27 | — | — | WO | claimed |
| CN-119698296-A | Anti-complement C1S antibody formulations | 美国比奥维拉迪维股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-118243923-A | Urine metabolism marker for diagnosing or monitoring bladder cancer and application thereof | 宁夏医科大学总医院 | 2024-06-25 | — | — | CN | claimed |
| US-20240117021-A1 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | BIOVERATIV USA INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20100239567-A1 | Antibody Formulation | GENENTECH, INC. (US) | 2010-09-23 | — | — | US | claimed |
| WO-2010102241-A1 | ANTIBODY FORMULATION | GENENTECH, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-7741282-B2 | ApO2 ligand/TRAIL formulations | GENENTECH, INC. (US) | 2010-06-22 | — | — | US | claimed |
| WO-2010057107-A1 | METHOD AND FORMULATION FOR REDUCING AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS | GENENTECH, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1450847-A4 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH INC (US) | 2007-08-29 | — | — | EP | claimed |
| JP-2005521640-A | — | — | 2005-07-21 | — | — | JP | claimed |
| US-20050080006-A1 | Apo2 ligand/trail formulations | GENENTECH, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050020498-A1 | Apo-2 ligand/trail formulations | GENENTECH, INC. | 2005-01-27 | — | — | US | claimed |
| EP-1450847-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003042344-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2003-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | GSR 4379/4885CYP1A2 4885/4885OTC 3847/4885 |
| US-20260009043-A1 | METHOD FOR PRODUCING SPERMIDINE | AHCYL1, AMD1, ALKBH5 | GSR 651/4885CYP1A2 4002/4885OTC 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.